Stock Analiz

CytomX Therapeutics, Inc. CTMX

Biotechnology: Pharmaceutical Preparations · IPO 2015 · data as of November 13, 2026

$2.04Market cap $445M
Open the interactive analysis →

CytomX Therapeutics, Inc. (CTMX) is a healthcare company listed in the US with a market value of about $445M. In the twelve months to September 30, 2026 it had revenue of $14M and net income of -$88M, a net margin of -630.3%.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 2% a year, a 5-year average ROIC of -95%.

About CytomX Therapeutics

CytomX Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2015. Revenue went from $5M in 2014 to $76M in 2025, growth of about 27.9% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 110% over three years (dilution for shareholders). It spends 90% of revenue on research and development.

Score: 0.8 / 5

Value0/5
Future growth2/5
Track record0/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • 3-year revenue growth above 10% a year
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S31.7
P/B1.6
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-11.5%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-44.8%
Revenue growth (5 yrs, per year)2.2%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-99.5%
ROIC (5-yr avg.)-95.4%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$14M$76M$138M$101M$53M$37M$68M$27M$60M$72M$15M
Net income-$88M-$17M$32M-$569000-$99M-$116M-$65M-$133M-$85M-$43M-$59M
Free cash flow-$51M-$76M-$87M-$57M-$113M-$121M$3M-$144M-$79M$169M-$4M
EPS (diluted)$-0.50$-0.15$0.38$-0.01$-1.51$-1.81$-1.40$-2.93$-2.03$-1.16$-1.63
Net margin-630.3%-22.8%23.1%-0.6%-186.8%-310.5%-94.7%-493.7%-142.2%-60.2%-391.5%
ROIC—-17.1%278.0%——-547.0%-387.9%-265.3%-45.3%-65.4%-75.9%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 8 analysts is $12.38, 507% above the current price; targets range from $5.00 to $16.00; the consensus rating is “Strong buy”; expected EPS is $-0.39 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does CytomX Therapeutics pay a dividend?

Not currently.

Is CytomX Therapeutics a good stock to buy?

We do not give buy or sell advice. CytomX Therapeutics scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.